

# Nanoplastics increase in vitro oestrogenic activity of neurotherapeutic drugs

---

**Božičević, Lucija; Vrčec, Valerije; Peranić, Nikolina; Kalčec, Nikolina; Vrčec, Ivana Vinković**

*Source / Izvornik:* **Arhiv za higijenu rada i toksikologiju, 2024, 75, 68 - 75**

**Journal article, Published version**

**Rad u časopisu, Objavljena verzija rada (izdavačev PDF)**

<https://doi.org/10.2478/aiht-2024-75-3818>

*Permanent link / Trajna poveznica:* <https://urn.nsk.hr/urn:nbn:hr:184:235430>

*Rights / Prava:* [Attribution 4.0 International](#)/[Imenovanje 4.0 međunarodna](#)

*Download date / Datum preuzimanja:* **2025-03-31**



*Repository / Repozitorij:*

[Repository of the University of Rijeka, Faculty of Medicine - FMRI Repository](#)





# Nanoplastics increase *in vitro* oestrogenic activity of neurotherapeutic drugs

Lucija Božičević<sup>1</sup>, Valerije Vrčec<sup>2</sup>, Nikolina Peranić<sup>1</sup>, Nikolina Kalčec<sup>1</sup>, and Ivana Vinković Vrčec<sup>1,3</sup>

<sup>1</sup> Institute for Medical Research and Occupational Health, Zagreb, Croatia

<sup>2</sup> University of Zagreb Faculty of Pharmacy and Biochemistry, Zagreb, Croatia

<sup>3</sup> University of Rijeka Faculty of Medicine, Rijeka, Croatia

[Received in January 2024; Similarity Check in January 2024; Accepted in March 2024]

Environmental pollution with plastic nanoparticles (PNPs) has rendered hazard assessment of unintentional human exposure to neurotherapeutic drugs through contaminated water and food ever more complicated. Due to their small size, PNPs can easily enter different cell types and cross different biological barriers, while their high surface-to-volume ratio enables higher adsorption of chemicals. This is how PNPs take the role of a Trojan horse as they enhance bioaccumulation of many different pollutants. One of the health concerns related to water pollution with neurotherapeutic drugs is endocrine disruption, already evidenced for the anticonvulsant drug carbamazepine (Cbz) and antidepressant fluoxetine (Flx). Our study aimed to evaluate endocrine disrupting effects of Cbz and Flx in mixtures with polystyrene nanoparticles (PSNPs) using the *in vitro* luciferase assay to measure oestrogen receptor activity in T47D-KBluc cells treated with Cbz-PSNPs or Flx-PSNPs mixtures and compare it with the activities observed in cells treated with individual mixture components (Cbz, Flx, or PSNPs). Dose ranges used in the study were 0.1–10 mg/L, 1–100 µmol/L, and 0.1–10 µmol/L for PSNPs, Cbz, and Flx, respectively. Our findings show that none of the individual components activate oestrogen receptors, while the mixtures induce oestrogen receptor activity starting with 0.1 mg/L for PSNPs, 10 µmol/L for Cbz, and 0.5 µmol/L for Flx. This is the first study to evidence that PSNPs increase oestrogen receptor activity induced by neurotherapeutic drugs at their environmentally relevant concentrations and calls for urgent inclusion of complex mixtures in health hazard assessments to inform regulatory response.

**KEY WORDS:** polystyrene; carbamazepine; fluoxetine; oestrogen receptors; T47D-KBluc cell line

Endocrine disrupting chemicals (EDCs) raise great health concerns for the global population. The strategic approach to deal with these substances in the European Union has been outlined in the Communication Towards a Comprehensive EU Framework on Endocrine Disruptors (1). EDCs interfere with the endocrine system and adversely affect the development, reproduction, metabolism, and the nervous and immune system (2) as they mimic body hormones that trigger and bind to cell receptors, blocking their interaction with natural hormones. Some EDCs interact with multiple receptors, and multiple EDCs interact with the same receptor (3). Interactions of EDCs with human organism can lead to several disorders such as obesity, diabetes, infertility, and endocrinopathies, as well as to hormone-dependent cancers (4).

Screening and testing for EDCs was initiated as high-priority in 1998 by the Organisation for Economic Co-operation and Development (OECD), which developed the test No. 455 (5) to evaluate oestrogenic activity and EDC interference with normal oestrogen signalling mediated by oestrogen receptors.

EDCs are highly diverse and include phytoestrogens in food, synthetic endocrine-acting chemicals in regulated birth control, hormone replacement and steroid medicines, non-hormonal

medicines (such as antipsychotics, antiepileptics, antihypertensives, antivirals, antidiabetics, and anticancer drugs), as well as environmental contaminants (such as pesticides, dioxins, perchlorates, phthalates, and polybrominated diphenyl ethers) (6). Our environment is being polluted with pharmaceuticals of all categories and their metabolites throughout their life cycle, most notably the aquatic environment, in which they are detected in low concentrations (measured in pg/L to µg/L) (7, 8). The general population is mostly exposed to them through drinking water, residues in leaf crops, root crops, fishery products, dairy products, and meat.

Health risks posed by pharmaceuticals in different environmental compartments cannot be clearly distinguished from the total risk of combined exposure with other chemicals and materials with potentially stronger impact on human health than exposure to individual components alone, even at concentrations regarded as safe. In this respect, the European Food and Safety Authority (EFSA) and the OECD have already provided guidance on how to assess risk from such mixtures (9–11).

Assessment is additionally challenged by plastic along its value chain. Plastic pollution is now considered one of the greatest

environmental issues due to its abundance and persistence in the aquatic environment (12). Plastics undergo various types of mechanical and biological degradation to micro- and nanoparticles (13), and nanoplastics can adsorb and accumulate toxic chemicals from the environment, acting as a “Trojan horse” for hazardous substances (14).

Our intent with this study was to contribute to human health hazard assessment by investigating for the first time the oestrogenic activity of complex mixtures of nanoplastics and neuroactive drugs. To this end we used selected, well characterised, commercially available polystyrene nanoparticles (PSNPs) combined with either carbamazepine (Cbz) or fluoxetine (Flx).

Cbz is an anticonvulsant for the treatment of epilepsy, bipolar disorder, and, more recently, neuropathic pain such as trigeminal neuralgia (15). It is often found in water bodies in a wide range from ng/L to µg/L and average concentration of 11.6 µg/L globally (16) or 12 µg/L in Europe (17). It is mostly neurotoxic as it lowers neuronal excitability, changes transmembrane transport, and regulates several neurotransmitters, but some studies evidence endocrine disruption, which causes imbalance in sex hormones and reproductive function impairment (15, 18, 19).

Flx is the third most prescribed selective serotonin reuptake inhibitor (SSRI) indicated for depression (20). Its average concentrations can reach 1.4 µg/L in the environment (11) and range between 0.5 and 0.8 ng/L in drinking water (21). In surface waters, it can reach 50 ng/L, as reported in the United Kingdom and some parts of Europe (22). Flx can have behavioural, neurotoxic, and endocrine disruptive effects (20, 23, 24). Several *in vitro* studies also reported disruption of steroid hormone production (25, 26) and interaction with oestrogen receptors (27, 28).

## MATERIALS AND METHODS

All testing was done in accordance with the EDC screening programmes devised by the OECD (5) and the United States Environmental Protection Agency (US EPA) (29) using the human-derived cell line T47D-KBluc.

### Characterisation of nanoparticles

PSNPs were purchased as a commercial stock of 25 nm particles in the concentration of 10,500 mg/L from Phosphorex (Hopkinton, MA, USA). They were visualised and their primary size ( $d$ , nm) determined with a transmission electron microscope (TEM) (JEOL JEM 1010, JEOL, Tokyo, Japan) in samples prepared by suspending them in the cell culture RPMI-1640 medium without phenol red (Sigma Aldrich, Steinheim, Germany) supplemented with 5 % charcoal-stripped foetal bovine serum (CS-FBS) (Sigma Aldrich) to obtain the concentration of 1 mg/L. The suspension was dropped on a Formvar<sup>®</sup>-coated copper grid (SPI Supplies, West Chester, PA, USA), dried overnight at room temperature, and measured in a bright field mode at an acceleration voltage of 80 kV. Images were

taken with a Canon PowerShot S50 Camera (Canon, Tokyo, Japan). Results are presented as mean values ( $d$ , in nm) of 60 particles with standard deviations (SD) calculated with the ImageJ software (LOCI, University of Wisconsin, Madison, WI, USA). Hydrodynamic diameter ( $d_{H}$ ) and size distribution were determined for PSNPs suspended in cell culture for 24 h and those not suspended in cell culture with dynamic light scattering and zeta potential using a Zetasizer Ultra instrument (Malvern Panalytical, Malvern, UK). Data were processed with the ZS Xplorer 3.21 software (Malvern Panalytical). The  $d_{H}$  results represent the means of six measurements expressed as intensity-weighted size distribution (in nm), while the zeta potential represents the means of three ELS measurements expressed in mV.

### Cell culturing

The T47D-KBluc cell line was purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). These are reporter-labelled cells transfected with triplet oestrogen-responsive elements used to screen for oestrogenic or anti-oestrogenic activity of chemicals (30). T47D-KBluc cells were cultured in tissue culture flasks (Sarstedt, Nümbrecht, Germany) with the RPMI-1640 medium supplemented with 10 % (v/v) CS-FBS and 1 % (v/v) antibiotic-antimycotic solution (Sigma Aldrich) at 37 °C and 5 % CO<sub>2</sub> to reach the density of 1×10<sup>6</sup> cells/mL (90–95 % confluence) before treatment.

### Cytotoxicity evaluation

Before we determined oestrogen receptor activity, we established dose-response cytotoxicity for PSNPs, Cbz, and Flx alone and for their mixtures. For that purpose, T47D-KBluc cells were seeded in 12-well plates (Sarstedt, Nümbrecht, Germany) containing 1 mL of cell culture medium at a density of 1×10<sup>5</sup> cells/well at 37 °C and 5 % CO<sub>2</sub>. After 24 h, we replaced the medium and treated the cells with different concentrations of test substances or their mixtures.

Dose ranges were selected based on literature data on *in vitro* toxicity of PSNPs, Cbz, and Flx (31–33) as follows: 0.1–10 mg/L for PSNPs, 3.75–500 µmol/L for Cbz, and 0.75–100 µmol/L for Flx. Their cytotoxicity was first tested with the MTS assay as described elsewhere (34) with the aim to find the doses at which >90 % cells remained viable. Negative controls were untreated cells and positive controls were cells treated with 10 % (v/v) DMSO (Sigma Aldrich).

After 48 h of treatment at 37 °C and 5 % CO<sub>2</sub>, the medium was removed from the plates into 2 mL Eppendorf tubes (Eppendorf, Hamburg, Germany). Cells remaining in the wells were washed with phosphate buffered saline (PBS) three times and then detached by incubating them with Trypsin-EDTA solution (Sigma Aldrich, Steinheim, Germany) at 37 °C and 5 % CO<sub>2</sub> for 5–7 min. The detached cells were then added to the Eppendorf tubes with previously collected medium.

Due to possible interferences with the MTS assay, cytotoxicity testing was then repeated using flow cytometry for PSNP doses of 0.1, 1, and 10 mg/L, for Cbz doses of 50 and 100  $\mu\text{mol/L}$ , and for Flx doses of 5 and 10  $\mu\text{mol/L}$ . Tube content (with viable and dead cells) was stained with Annexin V-FITC (AnnV) and propidium iodide (PI) using the flow cytometry Annexin V Kit (Bio Rad, Hercules, California, USA) to count live (AnnV-, PI-), early apoptotic (AnnV+, PI-), apoptotic (AnnV+, PI+), and dead cells (AnnV-, PI+) on a Cytoflex SRT sorter using its software (Beckman Coulter Life Sciences, Indianapolis, IN, USA).

Results are reported as the percentage of live, early apoptotic, late apoptotic, or dead cells compared to negative controls obtained from three independent experiments done in triplicate.

For further experiments we used only Cbz, Flx, and PNSP doses that left more than 90 % of cells viable to avoid bias that may arise from dead, unviable, or damaged cells.

### Measurement of oestrogen receptor activity

Oestrogen receptor activity in T47D-KBluc cells was determined for the test substances or their mixtures using the luciferase assay (Promega, Madison, WI, USA, Cat. Nos.: E1500 and E1501). The assay is based on the binding to oestrogen-responsive elements by oestrogen receptors that make part of the T47D-KBluc cell DNA sequence. Binding to these elements induces gene transcription that produces luciferase, which converts beetle luciferin (assay reagent) to a luminescent product oxyluciferin. The intensity of its luminescence is proportional to oestrogen receptor activation.

Our measurements followed the OECD test No. 455 (5). The responsiveness of the test system was checked using diethylstilbestrol (DES) as positive control and fulvestrant as negative control. The quality control of the assay confirmed  $\geq$ four-fold mean luciferase activity compared to negative/vehicle control on each plate and no interference by the test substances (PSNPs and neurodrugs) with the assay components and readouts.

The assay was run on T47D-KBluc cells that were first cultured for a week in a medium in which 10 % FBS was replaced by 10 % charcoal-stripped FBS to attenuate interferences from serum hormones. After one week, the cells were seeded in white opaque flat-bottom Nunc™ MicroWell™ 96-well microplates (Thermo Fisher Scientific, Waltham, MA, USA) at a density of  $2 \times 10^4$  cells per well, each containing 100  $\mu\text{L}$  of culture medium containing 5 % (v/v) charcoal-stripped FBS and kept there at 37 °C and 5 %  $\text{CO}_2$  for 24 h to attach to the wells. Followed a 48-hour treatment with different concentrations of PSNPs, Cbz, and Flx alone or their mixtures. Untreated cells were used as negative control and cells treated with 10 nmol/L DES as positive control. After the treatment, oestrogen receptor activity was measured on a SpectraMax iD3 microplate reader (Molecular Devices, San Jose, CA, USA) using the Promega luciferase assay kit as described above.

Results are expressed either as the percentage of fold luminescent signal inductions compared to negative or positive controls.


### Statistical analysis

Statistical analysis was run on GraphPad Prism6 (GraphPad Software, San Diego, CA, USA). Statistical significance was determined by one-way ANOVA followed by Dunnett's multiple comparison test with negative control values and set to  $P < 0.05$ .

## RESULTS AND DISCUSSION

### Physico-chemical characteristics and stability of PSNPs

Figure 1 shows the shape, size, size distribution, and zeta potential of the PSNPs used in this study. They were of spherical shape and primary diameter ( $d_{\text{TEM}}$ ) of  $25.6 \pm 3.2$  nm, confirming the producer's declaration (Phosphorex). Their hydrodynamic diameter ( $d_{\text{H}}$ ) was greater than  $d_{\text{TEM}}$  due to hydration and protein corona shell formation on the nanosurface, while further increase in  $d_{\text{H}}$  after 48 h indicates slight aggregation due to increased ionic strength of the cell culture medium (RPMI-1640). The zeta potential was negative and also increased after 48 h.



Measurement conditions (medium, incubation time)		
UPW, t = 0 h	CCM, t = 0 h	CCM, t = 48 h
$d_{\text{H}} = 26.7 \pm 2.9$ nm	$d_{\text{H}} = 51.8 \pm 6.1$ nm	$d_{\text{H}} = 91.4 \pm 8.9$ nm
$\zeta = -31.3 \pm 5.1$ mV	$\zeta = -9.1 \pm 2.2$ mV	$\zeta = -12.4 \pm 3.6$ mV

**Figure 1** Transmission electron micrograph (TEM) and physico-chemical properties of 10 mg/L polystyrene nanoparticles (PSNPs) in ultrapure water (UPW) and the RPMI-1640 cell culture medium (CCM) at baseline ( $t=0$  h) and after 48 h ( $t=48$  h) at 25 °C.  $d_{\text{TEM}}$  – PSNP dispersion in ultrapure water,  $d_{\text{H}}$  – PSNP hydrodynamic diameter in UPW and CCM;  $\zeta$  – PSNP zeta potential in in UPW and CCM

### Cytotoxicity of PSNPs, Cbz, Flx, and their mixtures

The MTS assay showed that doses below 60  $\mu\text{mol/L}$  for Cbz and below 12.5  $\mu\text{mol/L}$  for Flx did not affect the viability of T47D-KBluc cells (Figure 2), while the  $\text{IC}_{50}$  values were 174.8 and 30.17  $\mu\text{mol/L}$ , respectively.

Further flow cytometry showed that none of tested substances at given doses (0.1, 1, 5, and 10 mg/L for PSNPs; 1, 5, 10, 50, and 100  $\mu\text{mol/L}$  for Cbz; and 0.1, 0.5, 1, 5, and 10  $\mu\text{mol/L}$  for Flx) induced significant damage to the T47D-KBluc cells (Figure 3), so we proceeded with these doses in further luciferase assay experiments.

### Oestrogen receptor activity in cells exposed to PSNPs, Cbz, Flx, and their mixtures

Endocrine disrupting effects of Cbz and Flx in mixtures with PSNPs were determined by comparing cell oestrogen receptor

activity in respective mixtures (Cbz-PSNPs and Flx-PSNPs) with that of individual components (Cbz, Flx, or PSNPs). As described in the OECD test No. 455, a substance can be considered endocrine disruptor if oestrogen receptor response is equal to or exceeds 10 % of the response obtained with 10 nmol/L of DES. In view of these guidelines, the tested substances alone did not induce oestrogen receptor activity (Figure 4).

However, Cbz-PSNP and Flx-PSNP mixtures show quite alarming results in terms of health hazard and evidence that nanoplastics do behave like a Trojan horse in T47D-KBluc cells regardless of their concentration (Figure 5). Cbz and Flx mixed with PSNPs evoked strong endocrine disrupting response ( $\geq 10\%$  of oestrogen response to 10 nmol/L DES) starting with the doses of 50 and 1  $\mu\text{mol/L}$ , respectively.

Interestingly, oestrogen receptor response did not depend on PSNP concentrations. This may be owed to greater PSNP aggregation in the cell culture medium when particle concentrations are higher, which may decrease specific surface area available for interaction with cells and drug absorption. Furthermore, the observed response did not show dose dependence for the two higher drug doses (50 and 100  $\mu\text{mol/L}$  of Cbz, 5 and 10  $\mu\text{mol/L}$  of Flx), most likely because of nanosurface saturation.

### CONCLUSION


This *in vitro* study presents the first evidence of endocrine disrupting activity of complex mixtures containing polystyrene nanoparticles and neuroactive drugs. Our findings have confirmed our initial hypothesis that substances combined with nanoparticles will induce endocrine disruptive response at doses which do not provoke such response when applied alone. This calls for the revision of current health hazard assessment practices for environmental pollutants to include mixtures of plastic nanoparticles and pharmaceuticals in toxicity evaluation, considering that oestrogen receptor activation can lead to the development of various cancers mediated by various key events, such as increased proliferation and migration of cells, oxidative stress, non-genomic signalling and inflammatory response as evidenced by the AOP-Wiki, an open web platform launched by the OECD to support hazard assessment (35–37).

### Conflicts of interest


None to declare.

### Acknowledgements


This study was performed using the facilities and equipment funded as part of the European Regional Development Fund project KK.01.1.1.02.0007 “Research and Education Centre of Environmental Health and Radiation Protection – Reconstruction and Expansion of the Institute for Medical Research and Occupational Health”.




**Figure 2** Viability of T47D-KBluc cells treated with A) carbamazepine (Cbz) and B) fluoxetine (Flx) established with the MTS assay. Untreated cells were used as negative control (Ctrl) and cells treated with 10 % (v/v) DMSO as positive control (DMSO). Results are given as the percentage of Ctrl and calculated as mean values from three independent experiments. Standard deviations are given as error bars, and values that are significantly different from Ctrl are marked with \* ( $P < 0.05$ )



**Figure 3** Viability and apoptosis in T47D-KBluc cells treated with PSNPs, Cbz and Flx established with flow cytometry. Untreated cells were used as negative control (Ctrl) and cells treated with 10 % (v/v) DMSO as positive control (DMSO). Results are given as the percentage of live, early apoptotic, late apoptotic, and dead cells compared to Ctrl and calculated as mean values from three independent experiments. Standard deviations are given as error bars



**Figure 4** Oestrogen receptor activity in response to carbamazepine (Cbz), fluoxetine (Flx), and polystyrene nanoparticle (PSNP) treatment of T47D-KBluc cells. Results are shown as the percentage of fold induction of luminescent signal in comparison with positive control (10 nmol/L diethylstilbestrol, DES) and represent mean values from three independent experiments done in triplicate. Standard deviations (SD) are given as error bars. Values above the black line denote endocrine disrupting response according to the OECD test No. 455 (5)



**Figure 5** Oestrogen receptor activity in response to PSNP mixtures with (A) carbamazepine (Cbz) and (B) fluoxetine (Flx) in T47D-KBluc cells. Results are shown as the percentage of fold induction of luminescent signal in comparison with positive control (10 nmol/L diethylstilbestrol, DES) and represent mean values from three independent experiments done in triplicate. Standard deviations (SD) are given as error bars. Values above the black line denote endocrine disrupting response according to the OECD test No. 455 (5)

## REFERENCES

1. EUR-Lex. Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions - Towards a comprehensive European international investment policy /\* COM/2010/0343 final \*/ [displayed 5 March 2024]. Available at <https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=celex%3A52010DC0343>
2. Cho YJ, Yun JH, Kim SJ, Kwon HY. Nonpersistent endocrine disrupting chemicals and reproductive health of women. *Obstet Gynecol Sci* 2020;63:1–12. doi: 10.5468/ogs.2020.63.1.1
3. United Nations Environment Programme (UNEP), World Health Organization (WHO). State of the science of endocrine disrupting chemicals – 2012. Geneva: UNEP/WHO, 2012 [displayed 6 March 2024]. Available at: [https://iris.who.int/bitstream/handle/10665/78101/9789241505031\\_eng.pdf?sequence=1](https://iris.who.int/bitstream/handle/10665/78101/9789241505031_eng.pdf?sequence=1)
4. Rutkowska AZ, Diamanti-Kandaraki E. Polycystic ovary syndrome and environmental toxins. *Fertil Steril* 2016;106:948–58. doi: 10.1016/j.fertnstert.2016.08.031
5. OECD Guidelines for the Testing of Chemicals, Section 4. Test No. 455: Performance-Based Test Guideline for Stably Transfected Transactivation *In Vitro* Assays to Detect Estrogen Receptor Agonists and Antagonists, 2021 [displayed 5 March 2024]. Available at <https://doi.org/10.1787/9789264265295-en>
6. Sabir S, Akhtar MF, Saleem A. Endocrine disruption as an adverse effect of non-endocrine targeting pharmaceuticals. *Environ Sci Pollut Res Int* 2019;26:1277–86. doi: 10.1007/s11356-018-3774-4
7. Batucan NSP, Tremblay LA, Northcott GL, Matthaei CD. Medicating the environment? A critical review on the risks of carbamazepine, diclofenac and ibuprofen to aquatic organisms. *Environ Adv* 2022;7:100164–78. doi: 10.1016/j.envadv.2021.100164
8. Küster A, Adler N. Pharmaceuticals in the environment: scientific evidence of risks and its regulation. *Philos Trans R Soc Lond B Bio Sci* 2014;369(1656):20130587–95. doi: 10.1098/rstb.2013.0587
9. Batke M, Damm G, Foth H, Freyberger A, Gebel T, Gundert-Remy U, Hengstler J, Mangerich A, Partosch F, Röhl C, Schupp T, Wollin KM. The EU chemicals strategy for sustainability: critical reflections on proposed regulatory changes for endocrine disruptors and mixture toxicity. *Arch Toxicol* 2022;96:1133–5. doi: 10.1007/s00204-022-03227-z
10. McEntaggart K, Chirico S, Etienne J, Rigoni M, Papoutsis S, Leather J. EFSA EU Insights Chemical mixtures awareness, understanding and risk perceptions. *EFSA Support Publ* 2019;EN-1602. doi: 10.2903/sp.efsa.2019.EN-1602
11. OECD. Considerations for Assessment of Risk from the Combined Exposure to Multiple Chemicals. Series on Testing and Assessment No. 296, 2018 [displayed 5 March 2024]. Available at <https://www.oecd.org/chemicalsafety/risk-assessment/considerations-for-assessing-the-risks-of-combined-exposure-to-multiple-chemicals.pdf>

12. Sharma S, Chatterjee S. Microplastic pollution, a threat to marine ecosystem and human health: a short review. *Environ Sci Pollut Res Int* 2017;24:21530–47. doi: 10.1007/s11356-017-9910-8
13. Lehner R, Weder C, Petri-Fink A, Rothen-Rutishauser B. Emergence of nanoplastic in the environment and possible impact on human health. *Environ Sci Technol* 2019;53:1748–65. doi: 10.1021/acs.est.8b05512
14. Katsumiti A, Losada-Carrillo MP, Barros M, Cajaraville MP. Polystyrene nanoplastics and microplastics can act as Trojan horse carriers of benzo(a)pyrene to mussel hemocytes *in vitro*. *Sci Rep* 2021;11(1):22396. doi: 10.1038/s41598-021-01938-4
15. Mezzelani M, Peruzza L, D'Errico G, Milan M, Gorbi S, Regoli F. Mixtures of environmental pharmaceuticals in marine organisms: Mechanistic evidence of carbamazepine and valsartan effects on *Mytilus galloprovincialis*. *Sci Total Environ* 2023;860:160465. doi: 10.1016/j.scitotenv.2022.160465
16. Batucan NSP, Tremblay LA, Northcott GL, Matthaei CD. Medicating the environment? A critical review on the risks of carbamazepine, diclofenac and ibuprofen to aquatic organisms. *Environ Adv* 2022;7:100164. doi: 10.1016/j.envadv.2021.100164
17. Ács A, Liang X, Bock I, Griffiths J, Ivánovics B, Vásárhelyi E, Ferincz Á, Pirger Z, Urbányi B, Csenki Z. Chronic effects of carbamazepine, progesterone and their mixtures at environmentally relevant concentrations on biochemical markers of zebrafish (*Danio rerio*). *Antioxidants* 2022;11(9):1776. doi: 10.3390/antiox11091776
18. Almeida Á, Soares AMVM, Esteves VI, Freitas R. Occurrence of the antiepileptic carbamazepine in water and bivalves from marine environments: A review. *Environ Toxicol Pharmacol* 2021;86:103661. doi: 10.1016/j.etap.2021.103661
19. Mezzelani M, Nardi A, Bernardini I, Milan M, Peruzza L, d'Errico G, Fattorini D, Gorbi S, Patarnello T, Regoli F. Environmental pharmaceuticals and climate change: The case study of carbamazepine in *M. galloprovincialis* under ocean acidification scenario. *Environ Int* 2021;146:106269. doi: 10.1016/j.envint.2020.106269
20. Correia D, Domingues I, Faria M, Oliveira M. Effects of fluoxetine on fish: What do we know and where should we focus our efforts in the future? *Sci Total Environ* 2023;857:159486. doi: 10.1016/j.scitotenv.2022.159486
21. Nentwig G. Effects of pharmaceuticals on aquatic invertebrates. Part II: the antidepressant drug fluoxetine. *Arch Environ Contam Toxicol* 2007;52:163–70. doi: 10.1007/s00244-005-7190-7
22. Oakes KD, Coors A, Escher BI, Fenner K, Garric J, Gust M, Knacker T, Küster A, Kussatz C, Metcalfe CD, Monteiro S, Moon TW, Mennigen JA, Parrott J, Péry AR, Ramil M, Roennefahrt I, Tarazona JV, Sánchez-Argüello P, Ternes TA, Trudeau VL, Boucard T, Van Der Kraak GJ, Servos MR. Environmental risk assessment for the serotonin re-uptake inhibitor fluoxetine: Case study using the European risk assessment framework. *Integr Environ Assess Manag* 2010;6(Suppl):524–39. doi: 10.1002/ieam.77
23. Yamindago A, Lee N, Lee N, Jo Y, Woo S, Yum S. Fluoxetine in the environment may interfere with the neurotransmission or endocrine systems of aquatic animals. *Ecotoxicol Environ Saf* 2021;227:112931. doi: 10.1016/j.ecoenv.2021.112931
24. Correia D, Bellot M, Prats E, Gómez-Canela C, Moro H, Raldúa D, Domingues I, Oliveira M, Faria M. Impact of environmentally relevant concentrations of fluoxetine on zebrafish larvae: from gene to behavior. *Chemosphere* 2023;345:140468. doi: 10.1016/j.chemosphere.2023.140468
25. Lupu D, Sjödin MOD, Varshney M, Lindberg J, Loghin F, Rüegg J. Fluoxetine modulates sex steroid levels *in vitro*. *Clujul Med* 2017;90:420–4. doi: 10.15386/cjmed-868
26. Jacobsen NW, Hansen CH, Nellemann C, Styrisshave B, Halling-Sørensen B. Effects of selective serotonin reuptake inhibitors on three sex steroids in two versions of the aromatase enzyme inhibition assay and in the H295R cell assay. *Toxicol in Vitro* 2015;29:1729–35. doi: 10.1016/j.tiv.2015.07.005
27. Pop A, Lupu DI, Cherfan J, Kiss B, Loghin F. Estrogenic/antiestrogenic activity of selected selective serotonin reuptake inhibitors. *Clujul Med* 2015;88:381–5. doi: 10.15386/cjmed-474
28. Müller JC, Imazaki PH, Boaretto AC, Lourenço EL, Golin M, Vechi MF, Lombardi NF, Minatovicz BC, Scippo ML, Martino-Andrade AJ, Dalsenter PR. *In vivo* and *in vitro* estrogenic activity of the antidepressant fluoxetine. *Reprod Toxicol* 2012;34:80–5. doi: 10.1016/j.reprotox.2012.04.001
29. USEPA. Endocrine Disruptor Screening Program Test Guidelines - OPPTS 890.1300: Estrogen Receptor Transcriptional Activation (Human Cell Line (HeLa-9903)) [EPA 740-C-09-006] [displayed 5 March 2024]. Available at <https://www.regulations.gov/document/EPA-HQ-OPPT-2009-0576-0006>
30. Wilson VS, Bobseine K, Gray LE Jr. Development and characterization of a cell line that stably expresses an estrogen-responsive luciferase reporter for the detection of estrogen receptor agonist and antagonists. *Toxicol Sci* 2004;81:69–77. doi: 10.1093/toxsci/kfh180
31. Shen M, Zhang Y, Zhu Y, Song B, Zeng G, Hu D, Wen X, Ren X. Recent advances in toxicological research of nanoplastics in the environment: A review. *Environ Pollut* 2019;252:511–21. doi: 10.1016/j.envpol.2019.05.102
32. Ali I, Cheng Q, Ding T, Yiguang Q, Yuechao Z, Sun H, Peng C, Naz I, Li J, Liu J. Micro- and nanoplastics in the environment: Occurrence, detection, characterization and toxicity – A critical review. *J Clean Prod* 2021;313:127863. doi: 10.1016/j.jclepro.2021.127863
33. Xu JL, Lin X, Wang JJ, Gowen AA. A review of potential human health impacts of micro- and nanoplastics exposure. *Sci Total Environ* 2022;851:158111. doi: 10.1016/j.scitotenv.2022.158111
34. Malich G, Markovic B, Winder C. The sensitivity and specificity of the MTS tetrazolium assay for detecting the *in vitro* cytotoxicity of 20 chemicals using human cell lines. *Toxicology* 1997;124(3):179–92. doi: 10.1016/S0300-483X(97)00151-0
35. Sakuratani Y, Horie M, Leinala E. Integrated approaches to testing and assessment: OECD activities on the development and use of adverse outcome pathways and case studies. *Basic Clin Pharmacol Toxicol* 2018;123(Suppl 5):20–8. doi: 10.1111/bcpt.12955
36. Delrue N, Sachana M, Sakuratani Y, Gourmelon A, Leinala E, Diderich R. The adverse outcome pathway concept: A basis for developing regulatory decision-making tools. *Altern Lab Anim* 2016;44:417–29. doi: 10.1177/026119291604400504
37. Vinken M. The adverse outcome pathway concept: A pragmatic tool in toxicology. *Toxicology* 2013;312:158–65. doi: 10.1016/j.tox.2013.08.011



### Nanoplastika pojačava agonistički učinak neuroterapeutika u uvjetima *in vitro*

Onečišćenje okoliša nanočesticama plastike (PNP) dodatno je otežalo procjenu opasnosti od nenamjernog izlaganja ljudi neuroterapijskim lijekovima putem kontaminirane vode i hrane. Zbog svoje male veličine, PNP-i mogu lako ući u različite tipove stanica i prijeći različite biološke barijere, a njihov omjer površine i volumena omogućuje adsorpciju veće količine tvari na njihovu površinu. Upravo na taj način PNP-i preuzimaju ulogu trojanskoga konja te pospješuje bioakumulaciju mnogih zagađivača u ljudskom i drugim organizmima. Među štetnim učincima povezanim sa zagađenjem vode neuroterapijskim lijekovima jesu i poremećaji rada endokrinoga sustava. Takvi su učinci već dokazani za antikonvulzivni lijek karbamazepin (Cbz) i za antidepresiv fluoksetin (Flx). Našem je istraživanju cilj bio procijeniti endokrino disruptivne učinke Cbz i Flx u složenim smjesama s nanočesticama polistirena (PSNP) korištenjem luciferaznog eseja za ispitivanje aktivacije estrogenskih receptora u T47D-KBluc stanicama tretiranim smjesama Cbz-PSNP ili Flx-PSNP i usporediti ih s učincima koji su uočeni u stanicama tretiranim pojedinačnim komponentama smjese (Cbz, Flx ili PSNP). U istraživanju su korišteni ovi rasponi doza: 0,1 – 10 mg/L, 1 – 100  $\mu\text{mol/L}$  i 0,1 – 10  $\mu\text{mol/L}$  za PSNP, Cbz i Flx. Rezultati su pokazali kako niti jedna od pojedinačnih komponenti ne aktivira ER, a smjese induciraju aktivnost estrogenskih receptora, počevši od 0,1 mg/L za PSNP, 10  $\mu\text{mol/L}$  za Cbz i 0,5  $\mu\text{mol/L}$  za Flx. Ovo je prva studija koja dokazuje da PSNP-i povećavaju aktivnost estrogenskih receptora izazvanu neuroterapijskim lijekovima u njihovim ekološki relevantnim koncentracijama i poziva na hitno uključivanje procjene opasnosti od izloženosti složenim smjesama u procjene rizika za ljudsko zdravlje.

KLJUČNE RIJEČI: estrogenski receptori; fluoksetin; karbamazepin; polistiren; stanična linija T47D-KBluc